Intermediate risk prostate cancer: disease heterogeneity linked to measurable biological features
Affiliation
Translational Oncogenomics Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre, ManchesterIssue Date
2020
Metadata
Show full item recordCitation
Rebello RJ, Bristow RG. Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features. Clin Oncol (R Coll Radiol). 2020.Journal
Clinical OncologyDOI
10.1016/j.clon.2019.11.002PubMed ID
32147317Additional Links
https://dx.doi.org/10.1016/j.clon.2019.11.002Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2019.11.002
Scopus Count
Collections
Related articles
- Active surveillance in intermediate risk prostate cancer.
- Authors: Chandrasekar T, Herrera-Caceres JO, Klotz L
- Issue date: 2019 Mar
- Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
- Authors: Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT
- Issue date: 2017 Nov 15
- Active surveillance in intermediate-risk prostate cancer.
- Authors: Klotz L
- Issue date: 2020 Mar
- Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score.
- Authors: Pollard ME, Hobbs AR, Kwon YS, Katsigeorgis M, Lavery HJ, Levinson A, Bernstein AN, Collingwood SA, Hall SJ, Jazayeri SB, Samadi DB
- Issue date: 2017
- Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
- Authors: Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D
- Issue date: 2005 Mar 15